Semaglutide for renal insufficiency, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 28 Apr 2021: Trial started, NCT04865770
  2. 29 Apr 2021: Trial registered, NCT04865770

The trials

NCT04865770: A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

State
Completed
Phase
Phase 3
People
106 taking part
Started
28 Apr 2021
Primary completion
21 Nov 2024
Arms
Semaglutide 1.0 mg OW
Results
Posted on the registry
  1. 28 Apr 2021: Trial started
  2. 29 Apr 2021: Trial registered
  3. 21 Nov 2024: Trial completed
  4. 14 Jan 2026: Trial results posted

NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

State
Completed
Phase
Phase 2
People
626 taking part
Started
1 Apr 2024
Primary completion
24 Sep 2025
Arms
Semaglutide
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 1 Apr 2024: Trial started
  3. 6 Nov 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.